Myelofibrosis

Latest News

The Evolving Landscape of Polycythemia Vera Treatment
The Evolving Landscape of Polycythemia Vera Treatment

April 14th 2025

Current treatment strategies are aimed at reducing hematocrit and symptom burden through phlebotomy, aspirin, and cytoreductive agents, while emerging therapies offer promise for better disease control and quality of life.

Depiction of anemia, reduced red blood cells in bloodstream | Image Credit: © Prime Stox - stock.adobe.com
MANIFEST-2 Study: Pelabresib Plus Ruxolitinib Is Superior to JAK Inhibitors Alone

April 4th 2025

Diagnosis of Myelofibrosis. Laboratory blood bottle (tube), glass slide with blood smear, hematology test, stethoscope lying on notebook with printed text hematological diagnosis
Optimal Ruxolitinib Dosing in Myelofibrosis Critical for Improved Effectiveness, Survival in Real-World Setting

March 27th 2025

Blood Clot or thrombus blocking the red blood cells stream within an artery or a vein 3D rendering illustration.
Thrombosis, Major Bleeding Events More Frequent in Myelofibrosis Compared With Other Myeloproliferative Neoplasms

March 26th 2025

Blood Sample Analysis for IDH1 and IDH2 Mutations in Tumor Detection: CNS Gliomas Cholangiocarcinoma AML MPNs and PMF Diagnostics
Allo-SCT, Myeloablative Conditioning With Busulfan/Fludarabine Improves Survival in Myelofibrosis

March 20th 2025

More News

Fast Track Designation Granted for Relapsed/Refractory Myelofibrosis Treatment

Fast Track Designation Granted for Relapsed/Refractory Myelofibrosis Treatment

October 1st 2019

Officials from the FDA have granted Geron Corporation’s imetelstat fast track designation for adult patients with intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment.

Read More

FDA Grants Priority Review to Investigational Treatment for Myelofibrosis

FDA Grants Priority Review to Investigational Treatment for Myelofibrosis

March 5th 2019

If approved, fedratinib would be the second FDA-approved treatment for myelofibrosis.

Read More

<123